Kenjiro Ono

Department of Neurology,
Kanazawa University Graduate School of Medical Sciences
Kanazawa | Japan

Education

1997  M.D.  Showa University School of Medicine
2002  Ph.D. Kanazawa University Graduate School of Medical Science

Research and Professional Experience:

2007-2009        Postdoctoral Scholar, Department of Neurology, David Geffen School of Medicine, UCLA
2009-2011        Instructor, Department of Neurology, Kanazawa University Hospital
2011-2015        Associate Professor, Department of Neurology, Neurobiology and Aging, Kanazawa University Graduate School of Medical Science
2015-2016        Professor, Department of Neurology, Showa University School of Medicine, Tokyo, Japan
2016-2021               Professor and Chairman, Department of Neurology, Showa University School of Medicine, Tokyo, Japan
2021-                 Professor and Chairman, Department of Neurology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan (official offer)
Visiting Professor, Department of Neurology, Showa University School of Medicine, Tokyo, Japan
2022- 2025        Visiting Professor, Department of Oral and Maxillofacial Functional Rehabilitation, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan
2023-   　　　 Visiting Professor, Department of Neurology, Keio University School of Medicine, Tokyo, Japan
Visiting Professor, Department of Neurology, Jikei University School of Medicine, Tokyo, Japan
Visiting Professor, Department of Neurology, Toyama University, Toyama, Japan
Visiting Professor, Department of Neurology, Kanazawa Medical University, Kanazawa, Japan
Visiting Professor, Department of Neurology, Fujita Medical University, Aichi, Japan
Visiting Professor, Department of Neurology, Fukuoka University School of Medicine, Fukuoka, Japan
2024-                 Visiting Professor, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences

Awards and Honors:

2010                 The Award of Showa University School of Medicine Alumni Association
2013 　　　　10th Kanazawa University Medical Award
2015                 Japanese Society of Neurology Award
2016                 Medical Research Encouragement Prize of The Japan Medical Association
The Award for Distinguished Investigator of Japanese Society for Neurochemistry
2017　　　　 Japanese Society of Neurological Therapeutics Award

                        Kazato Prize (Kazato Research Foundation)

Selected 15 Publications:

1. Ono K., Hasegawa K., Yamada M., Naiki H. (2002) Nicotine breaks down preformed Alzheimer’s β-amyloid fibrils in vitro. Biol. Psychiatry 52, 880-886.
2. Ono K., Condron M.M., Ho L., Wang J., Zhao W., Pasinetti G.M., Teplow D.B. Effects of grape seed-derived polyphenols on amyloid β-protein self-assembly and cytotoxicity. J. Biol. Chem. 283, 32176-32187.　(Scopus Citation Index: 182) This article was selected as “JBC Paper of the week”.
3. Ono K., Condron M.M., Teplow D.B. (2009) Structure-neurotoxicity relationships of amyloid β-protein oligomers. Proc. Natl. Acad. Sci. U. S. A. 106, 14745-14750.
4. Hamaguchi T., Ono K., Murase A., Yamada M. (2009) Phenolic compounds prevent Alzheimer’s pathology through different effects on the amyloid β aggregataion pathway. Am. J. Pathol. 175, 2557-2565.
5. Ono K., Condron M.M., Teplow D.B. (2010) Effects of the English (H6R) and Tottori (D7N) familial Alzheimer disease mutations on amyloid β-protein assembly and toxicity. J. Biol. Chem. 285, 23186-23197.
6. Ono K., Li L., Takamura Y., Yoshiie Y., Zhu L., Han F., Mao X., Ikeda T., Takasaki J., Nishijo H., Takashima A., Teplow D.B., Zagorski M.G., Yamada M. (2012) Phenolic compounds prevent amyloid β-Protein oligomerization and synaptic dysfunction by site specific binding. J. Biol. Chem. 287, 14631-14643.
7. Umeda T., Ono K., Sakai A., Yamashita M., Mizuguchi M., Klein W.L., Yamada M., Mori H., Tomiyama T. (2016) Rifampicin is a candidate preventive medicine against amyloid β and tau oligomers. Brain 139, 5835-5840. This article was selected as “Brain Editor’s Choice, May, 2016”.
8. Watanabe-Nakayama T. ^#, Ono K. ^#, Itami M., Takahashi R., Teplow D.B., Yamada M. ^#Equally contributed. (2016) High-speed atomic force microscopy reveals structural dynamics of amyloid β1-42 aggregates. Proc. Natl. Acad. Sci. U. S. A. 113, 5835-5840.
9. Yasumoto T., Takamura Y., Tsuji M., Watanabe-Nakayama T., Imamura K., Inoue H., Nakamura S., Inoue T., Kimura A., Yano S., Nishijo H., Kiuchi Y., Teplow D.B., Ono K. (2019) High-molecular-weight amyloid β_1-42 oligomers induce neurotoxicity via plasma membrane damage. FASEB J. 33, 9220-9234.
10. Watanabe-Nakayama T., Nawa M., Konno H., Kodera N., Ando T., Teplow D.B., Ono K. (2020) Self- and Cross-Seeding on α-Synuclein Fibril Growth Kinetics and Structure Observed by High-Speed Atomic Force Microscopy. ACS Nano 14, 9979-9989.
11. Kimura A.M., Tsuji M., Yasumoto T., Mori Y., Oguchi T., Tsuji Y., Umino M., Umino A., Nishikawa T., Nakamura S., Inoue T., Kiuchi Y., Yamada M., Telow D.B., Ono K. (2021) Myricetin prevents high molecular weight Aβ_1-42 oligomer-induced neurotoxicity through antioxidant effects in cell membranes and mitochondria. Free Radic. Biol. Med. 171, 232-244.
12. Watanabe-Nakayama T., Tsuji M., Umeda K., Oguchi T., Konno H., Noguchi-Shinohara M., Kiuchi Y., Kodera N., Teplow D.B., Ono K. （2023） Structural Dynamics of Amyloid-β Protofibrils and Actions of Anti-Amyloid-β Antibodies as Observed by High-Speed Atomic Force Microscopy. Nano Lett 23, 6259-6268.
13. Noguchi-Shinohara M., Sakashita Y., Nakano H., Muramatsu D., Hikishima S., Komatsu J., Murakami H., Mori Y., Ono K. *Corresponding author. （2025）Plasma amyloid-β precursor protein 669-711/amyloid-β1-42 ratio is associated with cognition in Alzheimer’s disease. J. Prev. Alzheimers Dis. 12, 100003.
14. Muramatsu D., Nakayama-Watanabe T., Tsuji M., Umeda K., Hikishima S., Nakano H., Sakashita Y., Ikeda T., Konno H., Kodera N., Ando T., Noguchi-Shinohara M. Ono K*. *Corresponding author. (2025) ALZ-801 prevents amyloid β-protein assembly and reduces cytotoxicity: A preclinical experimental study. FASEB J. 39, e70382.
15. Noguchi-Shinohara M., Shuta K., Murakami H., Mori Y., Komatsu J., Kobayashi C., Hersch S., Horie K., Ono K. (2025) Lecanemab-Associated Amyloid-β Protofibril in Cerebrospinal Fluid Correlates with Biomarkers of Neurodegeneration in Alzheimer’s Disease. Ann. Neurol. 97, 993-1006.